Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium

Ross Camidge, Laurie Gaspar, Glennwood Goss, Karen Kelly, Suresh Ramalingam, Karen Reckamp, George Simon, Ming Tsao, Howard West, Roy Herbst, David Johnson, Paul Bunn, Ramaswamy Govindan

Research output: Contribution to journalArticle

Abstract

Lung cancer is the leading cause of cancer-related death in the United States. Outcomes for patients with lung cancer have reached a plateau with cytotoxic chemotherapy. Lung cancer remains very much at the vanguard of the new revolution in cancer therapy using molecular targets. Although striking improvements in survival have been observed in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and in a subset of breast cancer using this approach, the impact of targeted therapies in lung cancer is quite modest. Along with advances in imaging and cancer genomics, there is now considerable optimism that the pace of progress in the treatment of lung cancer will accelerate in the next 10 years. As has been the custom for the past 8 years, leading experts in the biology, diagnosis and treatment of lung cancer met for three days to discuss current areas of research and future directions. This summary provides a brief snapshot of the discussions held at the 8th Annual Meeting on Targeted Therapies for Lung Cancer sponsored by the International Association for the Study of Lung Cancer in Santa Monica in early February 2008.

Original languageEnglish (US)
Pages (from-to)930-935
Number of pages6
JournalJournal of Thoracic Oncology
Volume4
Issue number7
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Lung Neoplasms
Therapeutics
Neoplasms
Gastrointestinal Stromal Tumors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Genomics
Breast Neoplasms
Drug Therapy
Survival
Research

Keywords

  • Genomics
  • Lung cancer
  • Molecularly targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. / Camidge, Ross; Gaspar, Laurie; Goss, Glennwood; Kelly, Karen; Ramalingam, Suresh; Reckamp, Karen; Simon, George; Tsao, Ming; West, Howard; Herbst, Roy; Johnson, David; Bunn, Paul; Govindan, Ramaswamy.

In: Journal of Thoracic Oncology, Vol. 4, No. 7, 07.2009, p. 930-935.

Research output: Contribution to journalArticle

Camidge, R, Gaspar, L, Goss, G, Kelly, K, Ramalingam, S, Reckamp, K, Simon, G, Tsao, M, West, H, Herbst, R, Johnson, D, Bunn, P & Govindan, R 2009, 'Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium', Journal of Thoracic Oncology, vol. 4, no. 7, pp. 930-935. https://doi.org/10.1097/JTO.0b013e3181a9a03b
Camidge, Ross ; Gaspar, Laurie ; Goss, Glennwood ; Kelly, Karen ; Ramalingam, Suresh ; Reckamp, Karen ; Simon, George ; Tsao, Ming ; West, Howard ; Herbst, Roy ; Johnson, David ; Bunn, Paul ; Govindan, Ramaswamy. / Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. In: Journal of Thoracic Oncology. 2009 ; Vol. 4, No. 7. pp. 930-935.
@article{2ae7b717bc844a6a925c7229602b314d,
title = "Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium",
abstract = "Lung cancer is the leading cause of cancer-related death in the United States. Outcomes for patients with lung cancer have reached a plateau with cytotoxic chemotherapy. Lung cancer remains very much at the vanguard of the new revolution in cancer therapy using molecular targets. Although striking improvements in survival have been observed in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and in a subset of breast cancer using this approach, the impact of targeted therapies in lung cancer is quite modest. Along with advances in imaging and cancer genomics, there is now considerable optimism that the pace of progress in the treatment of lung cancer will accelerate in the next 10 years. As has been the custom for the past 8 years, leading experts in the biology, diagnosis and treatment of lung cancer met for three days to discuss current areas of research and future directions. This summary provides a brief snapshot of the discussions held at the 8th Annual Meeting on Targeted Therapies for Lung Cancer sponsored by the International Association for the Study of Lung Cancer in Santa Monica in early February 2008.",
keywords = "Genomics, Lung cancer, Molecularly targeted therapy",
author = "Ross Camidge and Laurie Gaspar and Glennwood Goss and Karen Kelly and Suresh Ramalingam and Karen Reckamp and George Simon and Ming Tsao and Howard West and Roy Herbst and David Johnson and Paul Bunn and Ramaswamy Govindan",
year = "2009",
month = "7",
doi = "10.1097/JTO.0b013e3181a9a03b",
language = "English (US)",
volume = "4",
pages = "930--935",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "7",

}

TY - JOUR

T1 - Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium

AU - Camidge, Ross

AU - Gaspar, Laurie

AU - Goss, Glennwood

AU - Kelly, Karen

AU - Ramalingam, Suresh

AU - Reckamp, Karen

AU - Simon, George

AU - Tsao, Ming

AU - West, Howard

AU - Herbst, Roy

AU - Johnson, David

AU - Bunn, Paul

AU - Govindan, Ramaswamy

PY - 2009/7

Y1 - 2009/7

N2 - Lung cancer is the leading cause of cancer-related death in the United States. Outcomes for patients with lung cancer have reached a plateau with cytotoxic chemotherapy. Lung cancer remains very much at the vanguard of the new revolution in cancer therapy using molecular targets. Although striking improvements in survival have been observed in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and in a subset of breast cancer using this approach, the impact of targeted therapies in lung cancer is quite modest. Along with advances in imaging and cancer genomics, there is now considerable optimism that the pace of progress in the treatment of lung cancer will accelerate in the next 10 years. As has been the custom for the past 8 years, leading experts in the biology, diagnosis and treatment of lung cancer met for three days to discuss current areas of research and future directions. This summary provides a brief snapshot of the discussions held at the 8th Annual Meeting on Targeted Therapies for Lung Cancer sponsored by the International Association for the Study of Lung Cancer in Santa Monica in early February 2008.

AB - Lung cancer is the leading cause of cancer-related death in the United States. Outcomes for patients with lung cancer have reached a plateau with cytotoxic chemotherapy. Lung cancer remains very much at the vanguard of the new revolution in cancer therapy using molecular targets. Although striking improvements in survival have been observed in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and in a subset of breast cancer using this approach, the impact of targeted therapies in lung cancer is quite modest. Along with advances in imaging and cancer genomics, there is now considerable optimism that the pace of progress in the treatment of lung cancer will accelerate in the next 10 years. As has been the custom for the past 8 years, leading experts in the biology, diagnosis and treatment of lung cancer met for three days to discuss current areas of research and future directions. This summary provides a brief snapshot of the discussions held at the 8th Annual Meeting on Targeted Therapies for Lung Cancer sponsored by the International Association for the Study of Lung Cancer in Santa Monica in early February 2008.

KW - Genomics

KW - Lung cancer

KW - Molecularly targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=68549140259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549140259&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181a9a03b

DO - 10.1097/JTO.0b013e3181a9a03b

M3 - Article

C2 - 19550249

AN - SCOPUS:68549140259

VL - 4

SP - 930

EP - 935

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 7

ER -